HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy

Creative Commons License

Files in This Item:
cas12646.pdf1.65 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/59497

Title: Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
Authors: Shinohara, Nobuo Browse this author →KAKEN DB
Obara, Wataru Browse this author →KAKEN DB
Tatsugami, Katsunori Browse this author →KAKEN DB
Naito, Sei Browse this author
Kamba, Tomomi Browse this author →KAKEN DB
Takahashi, Masayuki Browse this author →KAKEN DB
Murai, Sachiyo Browse this author
Abe, Takashige Browse this author →KAKEN DB
Oba, Koji Browse this author →KAKEN DB
Naito, Seiji Browse this author →KAKEN DB
Keywords: Metastasis
molecular-targeted therapy
prognosis
renal cell carcinoma
risk classification
Issue Date: May-2015
Publisher: Wiley-Blackwell
Journal Title: Cancer science
Volume: 106
Issue: 5
Start Page: 618
End Page: 626
Publisher DOI: 10.1111/cas.12646
Abstract: A multicenter cooperative study was conducted to clarify the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy and the clinical usefulness of the Japanese metastatic renal cancer (JMRC) prognostic classification. Of 389 consecutive patients for whom treatment was started between 2008 and 2010 at 23 hospitals in Japan, 357 patients who received vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) or cytokine as initial systemic therapy were the subject of the present study. Patients were classified into three prognostic groups according to the JMRC prognostic classification. The endpoints were progression-free survival (PFS) and overall survival (OS) after the start of the initial treatment. The median PFS and OS for the entire cohort of 357 patients were 9.1 and 27.2months, respectively. VEGFR-TKI were selected for patients with multiple organ metastases, those with liver metastasis, and those with bone metastasis. The median PFS and OS were 11.0 and 23.2months and 5.4 and 38.2months in the VEGFR-TKI group and the cytokines group, respectively. The JMRC prognostic classification was useful as a prognostic model for PFS and OS (c-indexes: 0.613 and 0.630 in patients who initially received VEGFR-TKI and 0.647 and 0.642 in patients who received cytokines, respectively). The present study showed for the first time the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy. The JMRC prognostic classification may be clinically useful as a prognostic model.
Rights: http://creativecommons.org/licenses/by-nc-nd/4.0/
Type: article
URI: http://hdl.handle.net/2115/59497
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 篠原 信雄

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University